PK-MED
24.7.2024 09:01:28 CEST | Business Wire | Press release
PK MED, a French biotech company, privately owned, and established in 2019 by Truffle Capital, announced it has secured a non-dilutive DeepTech financing of € 1.5 million from Bpifrance. The funding will accelerate the company’s project PKM-02, an innovative cell-homing technology aiming to enhance bone marrow transplantation in several diseases with high unmet medical need, such as leukemias and hemoglobinopathies.
Allogenic Hematopoietic Stem Cell Transplantation (HSCT), also known as bone marrow transplantation, involves transferring hematopoietic stem cells from a healthy donor to a patient with depleted or dysfunctional bone marrow. In a broad range of hematologic disorders, this therapy can be curative and/or prolong a patient’s life. More than 25,000 allogenic HSCTs are performed per year in the US and EU, and the treatment’s success depends on sufficient hematopoietic stem cell seeding, engraftment, and expansion within the bone marrow of the patient. However, the fraction of transplanted cells able to make their way to the bone marrow, known as homing, is reported to be low (1-10%). In addition, many patients are not eligible for the procedure, due to limited donor matching and an aggressive conditioning regimen needed to obtain a successful engraftment of the donor cells. Thus, there is an urgent unmet medical need to enhance the homing and engraftment of the transplanted cells.
PK MED’s innovative approach for this PKM-02 project, is based on the development of a therapeutic implant locally injected into the patient's bone marrow prior to allogeneic HSCT. This drug-based unique technology, combined with a biodegradable scaffold, is aimed at increasing the homing of the transplanted cells, as well as their subsequent engraftment. PKM-02 has shown several promising in vitro results, and PK MED is currently initiating preclinical studies. PK MED is considering extending this innovative technology to other applications in tissue regeneration.
Gauthier Pouliquen, Ph.D., CEO of PK MED, comments: “The development of our local cell-homing implant and the support of Bpifrance are a proof of PK MED's technological excellence and its commitment to medicine. Our ambition is to significantly advance bone marrow transplantation and cell regeneration techniques, for the benefit of all patients with hematologic disorders.”
About PK MED
PK MED is a French biotechnology company, founded in 2019 by Truffle Capital, developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation. PK MED's unique expertise and technological know-how enable evolving existing systemic treatments into new, safer and more effective patented local therapies.
PK MED has developed a portfolio of projects in indications where medical needs are high, starting with gout (PKM-01) and Hematopoietic Stem Cells transplants (PKM-02).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724252487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pantheon Expands Middle East Presence With New Abu Dhabi Office and Senior Regional Appointment30.9.2026 12:56:00 CEST | Press release
Abu Dhabi office, based in ADGM, continues Pantheon’s global expansion to serve growing client demand in key markets such as the Middle EastFiras Mallah joins as Managing Director and Head of Middle East to lead capital formation with sovereign wealth funds, family offices, and financial institutions across the region Pantheon, a leading global private markets firm with approximately $84bn in assets under management, today announced the expansion of its presence in the Middle East with the opening of its first office in ADGM, the international financial center based in Abu Dhabi, alongside the appointment of Firas Mallah as Managing Director and Head of Middle East. Demand for access to private equity, infrastructure, and private credit strategies continues to build among sophisticated investors across the Middle East, who recognize Pantheon for its 40-year track record of innovation and expertise across primaries, secondaries and co-investment opportunities. Secondaries – pioneered by
Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair30.9.2026 12:45:00 CEST | Press release
Research shared at the 35th European Academy of Dermatology and Venereology (EADV) Congress highlights the benefits of multifunctional sunscreens, colloidal oat formulations addressing acne, hyperpigmentation, eczema, UV-related skin damage, and the impact of 5% minoxidil for alopecia. Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930489298/en/ New Neutrogena science showcased at EADV 2026 in Vienna, Austria Abstracts presented will share new evidence demonstrating how science-backed ingredients including niacinamide, trehalose, colloidal oat and 5% minoxidil can help address some of the most common skin and hair concerns consumers experience, including acne, oily skin, dry skin, hyperpigmentation, eczema, UV-rel
34% of Global Consumers Say They Are Worse Off Financially Than a Year Ago as Households Adapt to a New Era of Permanent Uncertainty, NIQ Finds30.9.2026 12:45:00 CEST | Press release
Latest NIQ Consumer Outlook survey and report reveals shoppers are becoming more selective, with more than $23 billion shifting away from mainstream-priced CPG products toward value and premium alternatives With over a third (34%) of global consumers saying they are financially worse off than they were a year ago, and another third (30%) saying they are financially better off, consumers are no longer waiting for economic conditions to improve. Around the world, households are adapting to a future where volatility remains a persistent reality, creating increasingly different financial outcomes, spending priorities, and pathways to growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930542911/en/ NIQ's Consumer Outlook: Guide to 2027 These findings come from NielsenIQ’s (NYSE: NIQ) latest global Consumer Outlook survey of more than 21,000 respondents across 31 countries, combined with NIQ's measurement of real-world purc
NIQ Expands Google Relationship with Meridian Integration into NIQ Cadence™30.9.2026 12:30:00 CEST | Press release
Meridian, Google’s open-source Marketing Mix Modeling (MMM), is now available within NIQ Cadence™, accelerating the path from measurement to continuous marketing optimization in one connected workflow. NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its relationship with Google through the integration of Meridian, Google's open-source MMM framework, into NIQ Cadence™, NIQ's AI-native marketing effectiveness operating system. The strategic partnership gives marketers a single place to measure marketing performance and act on it, shortening the distance between insights and optimization. Marketing leaders are under growing pressure to prove the return on every media dollar, and traditional measurement has struggled to keep pace. In NIQ’s latest CMO Report, 74% of CMOs said they were under more scrutiny to prove marketing ROI, while just 9% felt they had adequate access to real-time insights. NIQ Cadence™ was built to help close the 65-point acti
Compass Pathways Appoints Kelley Boucher as Chief People Officer30.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027. "We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass’ journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin," said Kabir Nath, Chief Executive Officer a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom